Table 1.
Characteristics of 19 randomized controlled clinical trials included in the meta-analysis
| Author/year | Phase | Underlying malignancies | Patients enrolled | Treatment arm | Median age (years) | Median treatment duration (months/cycles) | Median PFS/TTF (months) | Number of patients for analysis | Number of VTEs | Number of ATEs | Jadad score |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandler et al. 2000 [25] | III | NSCLC | 522 | GEM 1000 mg m−2 + CDDP q.4.w. | 62 | 4 cycles | 5.6 | 260 | NR | 4 | 2 |
| CDDP q.4.w. | 63 | 4 cycles | 3.7 | 262 | NR | 1 | |||||
| Scagliotti et al. 2002 [26] | III | NSCLC | 620 | GEM 1000 mg m−2 + CDDP q.4.w. | 63 | 9.4 | 4.6 | 197 | 1 | 4 | 2 |
| PTX+CBP q.4.w. | 62 | 8.7 | 4.6 | 194 | 2 | 1 | |||||
| NVB+CDDP q.4.w. | 63 | 8.2 | 3.8 | 198 | 2 | 1 | |||||
| Sculier et al. 2002 [24] | III | NSCLC | 284 | GEM 1000 mg m−2 + CDDP+CBP q.4.w. | NR | NR | 86 days | 92 | NR | 4 | 2 |
| IFO+GEM q.4.w. | NR | NR | 84 days | 94 | NR | 0 | |||||
| CDDP+IFO+CBP q.4.w. | NR | NR | 84 days | 94 | NR | 3 | |||||
| Comella et al. 2004 [28] | II | NSCLC | 264 | GEM 1200 mg m−2 q.4.w. | 75 | 3 cycles | 3.3 | 68 | NR | 2 | 3 |
| PTX q.4.w. | 72 | 3 cycles | 3.7 | 63 | NR | 3 | |||||
| GEM 1000 mg m−2 + NVB q.3.w. | 72 | 3 cycles | 4.1 | 68 | NR | 1 | |||||
| GEM+PTX q.3.w. | 73 | 3 cycles | 4.5 | 65 | NR | 3 | |||||
| Georgoulias et al. 2005 [29] | III | NSCLC | 413 | GEM 1000 mg m−2 + DOC q.3.w. | 63 | 4 cycles | NR | 197 | NR | 1 | 2 |
| NVB+DDP q.3.w. | 64 | 4 cycles | NR | 192 | NR | 0 | |||||
| Lutz et al. 2005 [41] | II | Pancreatic cancer | 96 | GEM 800 mg m−2 + DOC q.3.w. | 58 | 4 cycles | 3.9 | 45 | 1 | NR | 2 |
| TXT+DDP q.3.w. | 59 | 4 cycles | 2.8 | 44 | 0 | NR | |||||
| Tan et al. 2005 [30] | III | NSCLC | 316 | GEM 1000 mg m−2 + NVB q.3.w. | 59 | 4 cycles | 3.9 | 154 | 5 | NR | 2 |
| NVB+CBP q.3.w. | 60 | 4 cycles | 4.4 | 155 | 1 | NR | |||||
| Fountzilas et al. 2006 [43] | II | Head and neck cancer | 166 | GEM 1000 mg m−2 + PTX q.3.w. | 63 | NR | 4.4 | 85 | NR | 3 | 2 |
| PTX+PLD q.3.w. | 65 | NR | 6.0 | 81 | NR | 1 | |||||
| Leong et al. 2007 [31] | II | NSCLC | 135 | GEM 800 mg m−2 q.4.w. | 72 | 2 cycles | 3.42 | 43 | 1 | NR | 2 |
| NVB q.4.w. | 73 | 2 cycles | 2.99 | 45 | 0 | NR | |||||
| TXT q.4.w. | 72 | 2 cycles | 2.78 | 46 | 1 | NR | |||||
| Martin et al. 2007 [38] | III | MBC | 252 | GEM 1200 mg m−2 + NVB q.3.w. | 58 | 6 cycles | 6.0 | 123 | 1 | NR | 3 |
| NVB q.3.w. | 57 | 4 cycles | 4.0 | 125 | 2 | NR | |||||
| Ohe et al. 2007 [32] | III | NSCLC | 602 | GEM 1000 mg m−2 + CDDP q.3.w. | 61 | NR | 3.2 | 151 | 0 | NR | 2 |
| PTX+CBP q.3.w. | 63 | NR | 3.2 | 148 | 0 | NR | |||||
| CPT-11 + CDDP q.4.w. | 62 | NR | 3.3 | 147 | 0 | NR | |||||
| NVB+CDDP q.3.w. | 61 | NR | 3.0 | 146 | 1 | NR | |||||
| Brufsky et al. 2011 [39] | II | MBC | 191 | GEM 1500 mg m−2 + PTX+BEV q.4.w. | 55.2 | 6 cycles | 11.3 | 93 | 5 | NR | 3 |
| PTX+BEV q.4.w. | 57.5 | 6 cycles | 8.8 | 94 | 3 | NR | |||||
| Kosmidis et al. 2011 [33] | III | NSCLC | 398 | GEM 1000 mg m−2 + PTX q.3.w. | 59 | 4 cycles | 5.0 | 185 | 1 | NR | 3 |
| PTX+NVB q.4.w. | 62 | 3 cycles | 4.4 | 185 | 1 | NR | |||||
| Seidman et al. 2011 [40] | III | MBC | 475 | GEM 1000 mg m−2 + DOC q.3.w. | 57 | 6 cycles | 6.7 | 237 | 4 | NR | 2 |
| CAP+DOC q.3.w. | 54 | 6 cycles | 5.1 | 226 | 1 | NR | |||||
| Weissman et al. 2011 [34] | III | NSCLC | 383 | GEM 1000 mg m−2 + L-OHP q.3.w. | 63 | 4 cycles | 4.44 | 184 | 0 | NR | 3 |
| CBP+PTX q.3.w. | 64 | 4 cycles | 4.67 | 187 | 1 | NR | |||||
| EI-Khoueiry et al. 2012 [42] | II | Pancreatic cancer | 52 | GEM 1000 mg m−2 + SOR q.4.w. | 65 | 2 cycles | 2.3 | 37 | 3 | NR | 2 |
| SOR qd. | 66 | 2 cycles | 2.9 | 15 | 0 | NR | |||||
| Han et al. 2012 [35] | III | NSCLC | 313 | GEM 1250 mg m−2 + DDP q.3.w. | 56.5 | 6 cycles | 6.4 | 150 | 1 | NR | 3 |
| Gefitinib qd. | 57 | 163 days | 5.8 | 159 | 0 | NR | |||||
| Spigel et al. 2012 [37] | II | NSCLC | 110 | GEM 1500 mg m−2 + PEM+BEV q.4.w. | 76 | 2.5 cycles | 4.7 | 55 | 4 | 1 | 2 |
| PEM+CBP+BEV q.3.w. | 77 | 6 cycles | 10.2 | 55 | 4 | 0 | |||||
| Price et al. 2012 [36] | II | NSCLC | 111 | GEM 100 mg m−2 + Radiotherapy | 74 | NR | NR | 55 | NR | 1 | 2 |
| Radiotherapy | 75 | NR | NR | 56 | NR | 0 |
ATE, arterial thromboembolic event; BEV, bevacizumab; CBP, carboplatin; CDDP, cisplatin; CPT-11, irinotecan; DOC, docetaxel; GEM, gemcitabine; IFO, ifosfamide; L-OHP, oxaliplatin; MBC; metastatic breast cancer; NR, not reported; NSCLC, non-small-cell lung cancer; NVB, vinorelbine; PEM, pemetrexed; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; PTX, paclitaxel; q.4.w., every 4 weeks; q.3.w., every 3 weeks; qd, every day; SOR, sorafenib; TTF, time-to-treatment failure; VTE, venous thromboembolic event.